Business

Bausch Health's Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA(R)

LAVAL, QC / ACCESSWIRE / September 6, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsid...

articleBausch Health Companies Inc.September 6, 20233/company/bausch-health-companies-inc/news/bausch-healths-bausch-lomb-announces-disclosure-of-historical-and-pro-forma-financial-information-with-respect-to-acquisition-of-xiidrar
Bausch Health's Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA(R)

About this update from Bausch Health Companies Inc.

[{"type":"text","content":"Bausch Health's Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA(R)LAVAL, QC / ACCESSWIRE / September 6, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX:BHC), announced that it has disclosed certain historical and pro forma financial information with respect to its previously announced proposed acquisition of XIIDRA® (lifitegrast ophthalmic solution) 5% and certain other ophthalmology assets (the \"Acquisition\") on a Current Report on Form 8-K and on its SEDAR+ (www.sedarplus.ca) profile. In connection with the Acquisition, as previously disclosed, Bausch + Lomb anticipates incurring indebtedness (expected to be comprised principally of an incremental term loan and the issuance of senior secured notes), which is discussed in further detail in its Current Report on Form 8-K. The Company has filed a Current Report on Form 8-K in connection with the above, a copy of which is also available on its SEDAR+ (www.sedarplus.ca) profile.About Bausch HealthBausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.Forward-Looking StatementsThis news release may contain forward-looking statements, including statements related to the proposed Acquisition and the anticipated indebtedness to be incurred in connection with the Acquisition, which may generally be identified by the use of the words \"anticipates,\" \"hopes,\" \"expects,\" \"intends,\" \"plans,\" \"should,\" \"could,\" \"would,\" \"may,\" \"believes,\" \"subject to\" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materi...

More updates from Bausch Health Companies Inc.